Effect of Sea Weed (Ecklonia Cava Extract) on Blood Glucose and Insulin Level on Pre-diabetic Patients

Launched by KING SAUD UNIVERSITY · Apr 25, 2021

Keywords

ClinConnect Summary

Methods:

Study design:

Double-blind, Randomized-controlled trial that will be conducted from 1st March 2021 to 20th July 2021 in Saudi Arabia. Application of ethical approval will be applied to Institutional Review Board (IRB) at King Saud University (KSU). Written consent form will be obtained from all participants' prior the conduction of the study and they will be able to withdraw from the study any time for any reason.

Participants:

Participants will be eligible to participate in this study if they are diagnosed in their medical history as pre-diabetic patient aged between 18 and 65...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female aged between 18 and 65 years.
• • diagnosed in their medical history as pre-diabetic patient with fasting plasma glucose (FPG) between 100 and 125 mg dL-1.
• • blood pressure within the normal range (systolic blood pressure ≤ 140 mmHg, diastolic blood pressure ≤ 90 mmHg).
• • having no other health complications.
• Exclusion Criteria:
• • taking any treatment with either insulin or anti-diabetic drugs.
• • taking any other natural health products known to impact blood sugar, or polyphenol absorption (e.g. fish oil).
• • having liver, thyroid, or significant gastrointestinal disorders.
• • pregnant or lactation
• • currently Smoker.